WELL Health Technologies (WELL.TO) Buy, Sell…

WELL Health Technologies (WELL.TO)

4.17

-0.18 (4.14%)

as of Jun 19, 2026, 8:00:00 pm Market Open.

103 watching

HOLD

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Valuation has come to down significantly. Greater focus on organic growth. Potential to be a long-term dominant player. Taken on more debt.

Wealthica Track your Stocks in your Watch List

DON'T BUY

Covered his short in June, as it had fallen too far, too fast. If it stays expensive, it may end up a hedge for him again. If it starts growing into its valuation, it could be a long. It's down to the metrics. Right now, he'd avoid.

BUY

It should continue to integrate the telehealth side with traditional medicine. Got extended during the pandemic and has come back down to earth. Once the rotation from shareholders is over, the stock will continue to build a base on earnings and then move up. Recent numbers were decent and he has re-added.

DON'T BUY

Not a profitable company that will struggle with rising interest rates. Better places for capital. Wait until later date to invest. Business model in the long term will survive (healthcare will always be required).

WATCH

It continues to grow and execute and management has delivered, but the market isn't interested in this type of stock. It did a recent acquisition and financial raise. It is building a digital platform for doctors - patient records etc.

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. EPS of $0.03 beat estimates and revenues were also ahead of expectations at $115.68M. Revenues increased 573% yoy for the quarter. Management expects 2022 revenues to top $500M and the company should be profitable. Very good results. Unlock Premium - Try 5i Free

DON'T BUY

The founding CEO has an excellent track record. He owned his previous company which did well. The valuation ripped higher and got ahead of itself--not their fault. However, in healthcare tech, there are names with better PEs.

COMMENT

Is in the online health service business, a huge growth area. It's a younger growth story without great cash flow but well positioned in Canada in the online health field. Doesn't own but is on his radar screen.

Wealthica Track your Stocks in your Watch List

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The stock price should not go below $3. 5i did not expect shares to go this low. Investors are not reacting to fundamentals recently. Nothing has changed for the company. More acquisitions should happen. Management is following their 5 year plan and doing a good job. Unlock Premium - Try 5i Free

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The fundamental outlook has not changed. Their acquisition from 2021 is still to be proven. Sentiment is shifting towards telehealth with covid being less of a concern. Revenu growth should be good in 2022. The company is moving closer to profitability. Unlock Premium - Try 5i Free

HOLD

Electronic medical record software. Expectations are very high. Still in growth mode, so not profitable. Street's target is $11, with 60% growth expected next year. Overall, healthcare IT is an interesting space. Lots of competition. A hold. More research required before buying.

BUY ON WEAKNESS

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The entire sector has been weak. Investors have some reservations about dilution from the aggressive acquisition strategy. Still comfortable with the stock in the longer term. Unlock Premium - Try 5i Free

WEAK BUY

With covid, WELL and other tele health came into the spotlight. Their prices appreciated quickly. Now, we are seeing a move away with more competition and the vaccine. In terms of investing, there are better opportunities elsewhere. A good company in an industry that is growing, however.

DON'T BUY

Telehealth player, with more of an unfocused strategy. Whereas AKU is very focused.

BUY ON WEAKNESS

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. No concerns for the stock except for the short term volatility. The short report will affect it short term, but management is committed with no sellers. Insiders own 16%. Attractive around $5.75. Unlock Premium - Try 5i Free

Showing 16 to 30 of 42 entries

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

WELL Health Technologies (WELL.TO)